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Major depressive disorder (MDD) is a common, often severe illness of mood regulation that 
affects approximately 350 million people worldwide. Women are twice as likely to be diagnosed 
with depression compared to men, but the molecular mechanisms underlying this sex difference 
are unclear. Previous human postmortem studies suggest that there is a dysfunction of inhibitory 
gamma-aminobutyric acid (GABA) function and brain-derived neurotropic factor (BDNF) 
function across corticolimbic brain regions, including the basolateral amygdala (BLA).  
Interestingly, post-mortem brain tissue from depressed patients suggests that there might be a sex 
difference in the way GABA is affected in depression, with more robust deficits in women with 
depression. Proper GABA function is also crucial during adolescence, as disruption could lead to 
susceptibility to mood disorders in adulthood. In our translational approach, we used the Four 
Core Genotypes (FCG) mouse model, in which genetic and gonadal sex are decoupled, to 
examine how sex-related factors influence GABA- and BDNF-related gene expression in the 
BLA in both adulthood and development. In a cohort of chronically-stressed adult mice (N=12-
20/group) as well as in a cohort of gonadally-intact mice at three developmental time-points 
(N=19-26/group), we quantified the gene expression of five genes: Sst, a marker a marker of a 
GABA-interneuron subtype that preferentially targets distal dendrites of pyramidal cells; Gad67 
and Gad65, genes that code for rate-limiting enzymes of GABA synthesis; TrkB, a gene that 
codes for the BDNF receptor, and Bdnf, a gene that codes for BDNF protein. We found an 
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 v 
opposing effect of testosterone (similar to a typical male level) and male genetic sex (XY) on 
expression of Sst, with testosterone increasing Sst expression (p<0.04), but lower Sst expression 
in XY mice (p<0.04). This result also mirrored the behavioral results, with lower anxiety-like 
behavior in testosterone-treated mice, but higher anxiety-like behavior in XY mice. We also 
found genetic sex effects suggesting a differing developmental trajectory of the GABA and 
BDNF systems, where XY mice develop later than XX mice. Together, my findings highlight the 
complex relationship of sex-related factors on GABA- and BDNF-related gene expression 
through development that, if altered, could lead to adult psychopathology. 
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1.0  INTRODUCTION 
1.1 MDD 
Major Depressive Disorder (MDD) is a common, chronic, and often severe illness of altered 
mood regulation that affects approximately 350 million people worldwide [1]. Depression is 
characterized by sadness, irritability, low mood, and altered psychophysiology, which together 
disrupt normal daily functioning and familial relationships. Currently, there is no isolated cause 
of depression, no established mechanism, and an inconsistent response to present-day treatments 
[2].  
1.2 BASOLATERAL AMYGDALA IN MDD 
Human postmortem studies of depressed subjects suggest that the corticolimbic neural 
network of mood regulation is dysregulated in depression [3, 4]. The corticolimic brain regions 
include the dorsolateral prefrontal cortex (DLPFC; important for executive function, decision 
making, and mood regulation), the hippocampus (memory center), subgenual anterior cingulate 
cortex (sgACC; important for regulating emotional responses), and the basolateral amygdala 
(BLA; the “fear” center). The sgACC facilitates communication between the DLPFC and the 
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BLA [5, 6]. After processing emotionally salient stimuli from the environment, the BLA, 
together with cortical feedback, initiates behavioral responses [7]. fMRI neuroimaging studies 
suggest that patients with MDD abnormally process emotional stimuli and exhibit prolonged 
hyperactivity in the BLA in response to various adverse stimuli [8, 9]. However other studies 
report no significant difference in BLA activation between MDD patients and control subjects 
[10, 11]. Patients with other anxiety disorders, such as post-traumatic stress, social anxiety, and 
generalized anxiety have similar hyperactivity of the BLA [12].  
1.3 SEX DIFFERENCES IN MDD 
Women are twice as likely as men to be diagnosed with MDD in their lifetime. Symptom 
prevalence and severity differ between men and women, as women experience both more 
symptoms and higher symptom severity [13]. Additionally, women are more likely to have 
comorbid hyperphagia, hypersomnia, seasonal affective disorder, and an anxiety disorder along 
with MDD, but men are more likely to have comorbid substance abuse with MDD [14]. 
Interestingly, cross-cultural and epidemiological studies suggest that although women are more 
likely to report and seek medical assistance for their symptoms, this is not a contributing factor 
to the sex difference in MDD prevalence [15]. Thus, by controlling for potentially confounding 
variables, such as healthcare access, these studies suggest that the underlying cause for the sex 
difference in MDD incidence is biological. The sex differences in symptom prevalence and 
severity suggest that MDD progresses differently in men and women, with possibly different 
underlying biological mechanisms. Understanding depression in both sexes will not only 
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improve our understanding of MDD overall, but might also ultimately contribute to the 
development of sex-specific treatments for depression [16].  
1.4 GABA AND BDNF DYSFUNCTION IN MDD 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain and is 
present at each node of the corticolimbic circuit. Both magnetic resonance spectroscopy [17-19] 
and molecular studies [20, 21] demonstrate a GABA-deficit in MDD, which possibly leads to 
reduced GABA-mediated inhibition [22]. The decrease in GABA-inhibition within the circuit 
can lead to impaired excitation/inhibition balance in mood disorders [17, 20]. Previous studies 
conducted in our lab suggest a reduction in dendritic-targeting GABA interneurons in the sgACC 
[23, 24], DLPFC [25], and BLA [21] of MDD patients. Somatostatin (SST), a marker of a 
GABA-interneuron subtype that preferentially targets distal dendrites of pyramidal cells, was 
more robustly decreased in female subjects with MDD than men with MDD [23, 24, 26]. In the 
BLA, females MDD subjects have reduced SST, but depressed males do not [26]. GAD67 and 
GAD65 are genes that code for rate-limiting enzymes in GABA synthesis. There is a high level 
of SST, GAD67, and GAD65 found in human postmortem brains of MDD patients, suggesting a 
common function of these three genes or shared common regulatory pathways e.g. hormone 
signaling or transcription factors [26, 27].  Our human studies are supported by causal mouse 
studies in which slight reduction in GABA-signaling induces depressive-like behaviors [28]. 
Brain-derived neurotropic factor (BDNF), known for growth and neuronal survival in the brain, 
also exhibits altered expression in MDD [21]. A robust decrease of BDNF expression is found in 
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sgACC of both sexes and in the BLA of females specifically [21, 24]. There is also reduced 
expression of TrkB, the gene that codes for the BDNF receptor, in subjects with MDD [24]. This 
suggests there may also be an sex difference in BDNF-related signaling in the BLA of MDD 
subjects [16]. 
1.5 STUDYING SEX DIFFERENCES 
Our lab is interested in understanding the underlying biological mechanisms of these sex 
differences observed in MDD subjects. We investigate three types of sex differences: effects of 
genetic sex, effects of developmental gonadal hormone (organizational effects of hormones; 
leads to permanent, and thus irreversible, sex differences), and effects of adult circulating 
hormones (activational effects of hormones; leads to transient sex differences in adulthood) [29, 
30]. We are limited in our ability to clearly identify the underlying sex dependent mechanisms 
that could explain the observed human sex differences in MDD. For example, genetic sex always 
determines gonadal sex in humans; consequently, it is impossible to distinguish if the observed 
sex differences are driven solely by genetic sex or gonadal sex. We also do not know how 
circulating hormone levels of our postmortem subjects varied over their lifetime or at the time of 
death. Combined, these limitations interfere with our ability to discern specifically which sex-
related variables drive any of the observed sex differences in MDD.  Moving our studies to 
mouse models allows us to tightly control different sex-related factors and easily manipulate our 
system of interest [31]. We can study analogous brain regions in a mouse model to expand our 
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understanding of the overall circuit, as the corticolimbic circuit is comparable to that of humans 
[32, 33].  
1.6 FCG MICE 
Genetic sex drives gonadal sex in typical wildtype mice, which makes it difficult to identify the 
three major types of sex differences explained earlier. Genetic engineering, however, allows for 
us to take advantage of genetically modified mouse strains, such as the Four Core Genotypes 
(FCG) mice. Genetic sex and gonadal sex are decoupled in this model. Crossing a C57BL/6J 
female mouse with a XY-Sry (XYM) male (testes-determining gene, Sry, is located on an 
autosomal transgene instead of its endogenous location on the Y chromosome) allows for genetic 
sex and gonadal sex decoupling in this model. We can generate four different genotypes in which 
genetic sex does not determine gonadal sex: XXF (genetic and gonadal female), XYF (genetic 
male, gonadal female), XXM (genetic female, gonadal male), and XYM (genetic and gonadal 
male). Utilizing this model lets us independently analyze both genetic sex and gonadal sex 
effects, as well as better understand which component is responsible for observed sex 
differences. In addition to these genome manipulations, we also can control adult circulating 
hormone levels to examine activational effects of hormone.  
Our lab previously studied Sst, Gad67, and Gad65 expression in the frontal cortex of 
Four Core Genotypes (FCG) adult mice that were exposed to unpredictable chronic mild stress 
(see ‘Methods’). Interestingly, we found that chronically stressed XY mice, regardless of 
gonadal sex or circulating hormone, had lower expression of Sst, Gad67, and Gad65 compared 
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to XX mice. This was surprising to us given the increased female prevalence to MDD. However, 
XY mice also exhibited increased anxiety-like behavior, which is consistent with them having 
decreased Sst, Gad67, and Gad65 expression. As we predicted given previous findings, 
testosterone treatment strongly decreased anxiety-like behavior [34], but testosterone did not 
affect gene expression in the frontal cortex [26, 35]. This led us to hypothesize that in a healthy 
male, circulating testosterone may override the underlying vulnerability to increased anxiety-like 
behaviors caused by male genetic sex.  
It is interesting that while SST exhibits lower levels in the sgACC of both men and 
women, the SST reduction in the BLA is specific to females with MDD. This finding points to a 
potential sex difference in the BLA of MDD patients [26]. Human and mouse studies together 
support the hypothesis of an overall GABA dysfunction in MDD, but specifically a dysfunction 
of GABA in the BLA of females with MDD[16]. Additionally, there is a strong BDNF 
dysfunction in the BLA of female MDD patients, but not males [27]. Together, we hypothesized 
that the BLA is the brain region involved in the sex difference in MDD. In cohort 1, I aimed to 
test two alternative hypotheses: 1) there a brain-wide effect of genetic sex on GABA- and BDNF 
related genes; or 2) the genetic sex effect on GABA- and BDNF related genes is brain region-
specific.  
1.7 UNPREDICTABLE CHRONIC MILD STRESS 
Our lab uses UCMS, a behavioral paradigm designed to strongly increase anxiety- and 
depressive-like behavior and produce homologous features that are associated with human major 
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depressive disorder (MDD)[26, 36, 37]. UCMS induces a UCMS syndrome in mice with 
construct validity, face validity, and predictive validity. Construct validity refers to the mice 
exposed to and coping with small stressors over a long period of time as is often true in 
depression, rather than a singular traumatizing event, like post-traumatic stress disorder. Face 
validity refers to the observable increased anxiety- and depressive-like behaviors of the mice. 
Predicative validity refers to the use of antidepressant treatments to reverse the UCMS 
syndrome, just like in depression: one dose of antidepressant treatment will not reverse the 
UCMS syndrome, but chronic exposure to antidepressants does reverse the UCMS syndrome 
[16, 26].  
1.8 ADOLESCENCE AND GABA IN MOOD 
Adolescence is a transitional time in development that includes various physiological and 
behavioral changes between pre-puberty and adulthood that are not fully understood. Child abuse 
and neglect leads to stress and trauma during early development, which can affect mood disorder 
susceptibility in adulthood. The development of the GABA system specifically affects both the 
structure and the communication of the cortex. GABA originates as an excitatory 
neurotransmitter at birth, but becomes inhibitory during pre-pubertal stages of development [38]. 
The developing GABA system also contributes to cortical activity synchronization in 
adolescence [39]. Dysregulated cortical synchronization is believed to perhaps contribute to the 
development of MDD, as subjects with the disorder have increased synchronization of neuron 
firing [40]. This suspected developmental window of vulnerability overlaps with the well-known 
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developmental window for sex differences. Differences between male and female GABA 
function during adolescence could influence sex-specific synaptic development and/or cortical 
synchronization later in life. Ultimately, this could negatively impact cortical development and 
foreshadow vulnerability in adulthood for psychiatric disease, like MDD [16]. In cohort 2, I 
aimed to determine if genetic sex and/or organizational hormone influence GABA-related genes 
expression in the BLA of pre- and peri-pubertal mice.  
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2.0  METHODS 
2.1 MICE 
This study utilized a unique strain of mice called the Four Core Genotypes (FCG) mice. In a 
wildtype mouse, genetic sex and gonadal sex are entirely linked due to the testes-determining 
gene, Sry, on the Y chromosome. This means that if a wildtype organism has a Y chromosome, 
they have Sry, and therefore, will develop gonadally male (both genetically and gonadally male). 
If a wildtype organism does not have a Y chromosome, they do not have Sry, and therefore, will 
develop gonadally female (both genetically and gonadally female). Using genetic engineering, 
the Sry gene was removed from the Y chromosome and placed on an autosome instead, thereby 
decoupling genetic and gonadal sex.   
The FCG mice used in these studies (originating from Jackson Laboratories, Bar Harbor, 
ME, USA; B6.Cg- Tg(Sry)2Ei Srydl1Rlb/Arnoj) were generated by crossing a C57BL/6J female 
with an XY-Sry male. Y- indicates the absence of Sry on the Y chromosome, with Sry present 
instead as an autosomal transgene. Here, we use the male (M) and female (F) designation to 
indicate gonadal sex. This cross yielded four groups of mice: XXM (XXSry), XXF (XX), XYM 
(XY-Sry) and XYF (XY-). These four genotypes allow us to investigate the effects of genetic sex 
and developmental gonadal sex (i.e., organizational effects of hormones) independent of the 
other, as genetic sex and gonadal sex are inherited independently in this model. The addition of a 
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testosterone or blank capsule (discussed below) after gonadectomy in adulthood also allows us to 
investigate the effects of circulating hormones (i.e., activational effects of testosterone). The 
mice were maintained under standard conditions (12-hour light and dark cycles; 22 ± 1°C, food 
and water ad libitum), in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee. 
2.2 EXPERIMENT 1: ADULTS (COHORT 1) 
Adult FCG mice were bilaterally gonadectomized at 15 weeks under isoflurane anesthesia to 
remove the endogenous source of circulating gonadal hormone. Half of each genotype was 
implanted with a subcutaneous testosterone-filled capsule containing 5-mm crystalline 
testosterone (1.57-mm ID x 2.41-mm OD) or with a similarly sized blank capsule [16]. [XXF + 
B (n=12), XXF + T (n = 18), XYF + B (n=13), XYF + T (n=13), XXM + B (n=18), XXM + T (n 
= 13), XYM + B (n=12), XYM + T (n = 13)]. It is important to note that the concentration the 
testosterone capsules were at or slightly above physiologically normal male levels. After 
allowing 4 weeks for mice to recover from surgery and for hormone levels to equilibrate, the 
mice were exposed to 8 weeks of unpredictable chronic mild stress (UCMS; see details below). 
After 7 weeks of UCMS exposure, mice were assessed for anxiety-like behaviors in the elevated 
plus maze and open field. (Figure 1). Mice were exposed to UCMS during behavior testing, thus 
the mice were exposed to UCMS for a total of 8 weeks. 
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Figure 1: Experimental design for cohort 1.  
Mice were gonadectomized (GDX) at ~15 weeks of age and implanted subcutaneously with either a testosterone 
(T)-filled or blank capsule. After GDX, mice in cohort 1 were exposed to 8 weeks of unpredictable chronic mild 
stress (UCMS) followed by behavioral testing and were then sacrificed. At the time of sacrifice, the brains were 
harvested for gene expression analyses and bloods were collected for hormone assays [16].  
2.2.1 Unpredictable Chronic Mild Stress 
Group-housed adult mice (gonadal sex and hormone treatment matched) were exposed to a 
randomized schedule of environmental stressors 7 days a week for 8 weeks, gradually increasing 
in intensity, starting with 1–2 separate stressors a day and ending with 4–5 stressors a day 
(separately and in tandem with one another) during the final week, as performed previously in 
our lab [16, 26]. Disturbances included light cycle disruption, tilted cage (45° tilt), social stress 
(rotate mice into previously occupied cages), reduced space (limiting mice to 1/3 of typical space 
in cage), aversive smell (20 min of exposure to bobcat or fox urine), no bedding or wet bedding 
overnight, mild restraint (50-mL conical tube with air hole for 15 min), and forced bath 
(approximately 2 cm of 21°C water for 15–45 min). We assessed body weight and fur weekly to 
track progression of the UCMS syndrome. Behavior testing occurred while mice were still being 
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exposed to UCMS. We previously reported frontal cortex gene expression results from this 
cohort [16, 26, 35]. 
2.2.2 Behavioral Testing 
2.2.2.1 Elevated Plus Maze 
The elevated plus maze is a behavioral test used to measure anxiety-like behavior [41]. This 
cross maze was constructed with 2 open and 2 closed 30 cm x 5 cm arms. Performed during the 
light phase, the mouse was initially placed at the intersection of the four arms. Over 10 minutes, 
the amount of time spent in the open arms and percent entries (entries into open arms divided by 
entries into open or closed arm x 100) in the open arms were recorded to measure anxiety-like 
behavior. An index of locomotor behavior was indicated by the total number of entries into any 
arm [26, 42]. 
2.2.2.2 Open Field Test 
The open field test is a behavioral test used to measure anxiety-like behavior[43]. During the light 
phase, the open field test was performed in a 50.8 cm x 50.8 cm square arena. The centermost 
portion was identified at 25.4 cm X 25.4 cm of the arena. Behavior was tracked using ANY-
Maze software (Stoelting; Wood Dale, IL, USA) and a ceiling-mounted camera. Over 10 
minutes, the amount of time spent in the center of the arena and the percent distance (distance in 
the center divided by the total distance x 100) was recorded to measure anxiety-like behavior. An 
index of locomotor activity was indicated by the total distance traveled [26].  
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2.3 EXPERIMENT 2: DEVELOPMENTAL TRAJECTORY (COHORT 2) 
We decided to study time-points clearly before puberty (late postnatal) through early 
adolescence. We used FCG mice aged postnatal day 16 (P16), P21, and P26 [P16 (pre-weaning), 
P21 (at time of weaning), and P26 (post-weaning)]. P16 had 79 gonadally intact FCG mice [XXF 
(n=20), XYF (n=19), XXM (n=20), XYM (n=20)]. P21 had 88 gonadally intact FCG mice [XXF 
(n=22), XYF (n=26), XXM (n=21), XYM (n=19)]. P26 had of 80 gonadally intact mice [XXF 
(n=20), XYF (n=20), XXM (n=20), XYM (n=20)]. These groups were not exposed to stress and 
did not have circulating hormone manipulations. At the time of sacrifice, mice were rapidly 
decapitated. Brains were collected for gene expression studies (qPCR) and bloods were collected 
for the ELISA testosterone assay (Figure 2). 
 
 
Figure 2: Experimental design for cohort 2.  
Mice in cohort 2 were sacrificed at one of three developmental time-points: postnatal day 16, 21 or 26.  P16 and P21 
are both prior to the onset of puberty while P26 is closer to the onset of puberty. At the time of sacrifice, the brains 
were harvested for gene expression analyses and bloods were collected for testosterone hormone assays.   
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2.4 SACRIFICE AND TISSUE PROCESSING 
Mice were sacrificed at postnatal day 16, postnatal day 21, postnatal day 26, and week 24 (while 
adults were still being exposed to stressors), and the brains and bloods were collected. Adult 
mice were anesthetized by isoflurane and both adult and developmental mice were rapidly 
decapitated. The brains were dissected out and immediately flash frozen on dry ice. Trunk blood 
was collected, allowed to clot at room temperature for 90 min, and the serum separated out to 
measure testosterone levels [16]. 
2.5 TESTOSTERONE ASSAY 
Circulating testosterone levels of this cohort were measured from collected serum samples. In 
adults, the serum samples were sent to the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core (supported by the Eunice Kennedy Shriver 
NICHD/HIH (SCCPIR) Grant U54-HD28934), and an ELISA kit was used to determine 
testosterone concentration. Using the same ELISA kit and protocol as the ones used at University 
of Virginia, we measured circulating testosterone levels of P16, P21 and P26 mice by using a 
testosterone (mouse/rat) ELISA assay (IBL America; Minneapolis, MN) in accordance with kit 
instructions. Subjects found to be statistical outliers by using the Graphpad Grubb’s Outlier Test 
were excluded from qPCR analysis [16].  
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2.6 PROCESSING OF BRAIN TISSUE: BLA DISSECTION AND GENE 
EXPRESSION ANALYSIS  
Bilateral micropunches (1mm bore punch) of the BLA (between Bregma −0.94 and −1.82 mm; 
[31]) were obtained from approximately six 160-μm thick coronal tissue sections cut on a 
cryostat within the boundaries created by the internal and external capsule. All tools were treated 
with RNase Zap to prevent RNases contamination. Punches were stored in RNase free 1.5mL 
tubes at −80°C prior to RNA extraction [16]. 
2.7 RNA EXTRACTION AND CDNA SYNTHESIS 
Total RNA was extracted from BLA tissue punches using RNeasy Plus Micro Kits (Qiagen; 
Valencia, CA, USA). RNA was reverse-transcribed into complementary DNA (cDNA) using 
QScript cDNA Supermix (olido(dT) and random primers (Quanta Biosciences, Gaithersburg, 
MD, USA)) [16].  
2.8 QUANTITATIVE POLYMERASE CHAIN REACTION 
In the adult cohort, small PCR products were amplified on a MJ Research (Waltham, MA, USA) 
DNA Engine Opticon System for qPCR using universal PCR conditions (65 to 59 °C touch-
down and 40 cycles (10 s at 95°C, 10s at 59°C, and 10s at 72°C)). cDNA was amplified in 20-μL 
reactions (0.1 × SYBR Green, 3 mM MgCl2, 200 nM dNTPs, 200 nM primers, 0.25 unit 
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Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA)) [16]. In the developmental 
trajectory cohort, gene expression was measured using CFX96 Touch™ Real-Time PCR 
Detection System using the following PCR conditions (5s at 95°C, 30s at 60°C) for 39 cycles. 
cDNA was amplified in 20 μL reactions (10 μL supermix (add official name), 9 μL primer 
associated with gene of interest, and 1 μL cDNA in each well) [16]. 
Samples were run in triplicate, and results were calculated as the geometric mean of 
relative intensities compared to three internal controls (actin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), and cyclophilin). Actin, GAPDH, and cyclophilin are considered 
good housekeeping genes because sex-related factors do not influence their expression or 
abundance, thus we consider them to be internal controls. The results are expressed as arbitrary 
signal (2-dCT × 10,000). We eliminated actin from the P26 experiments because it was not 
strongly correlated with the other two housekeeping genes. The arbitrary signals in the P26 
study, then, were calculated from the geometric mean of cyclophilin and GAPDH. Genes of 
interest (Sst, Gad67, Gad65, TrkB, and Bdnf) were selected based on our human postmortem 
brain findings in depression. Grubbs’ outlier test determined statistical outliers in gene 
expression values. These outliers were excluded from qPCR analysis [16]. I performed qPCR for 
P16 and P26 groups, while another lab member ran qPCR for the P21 group.  
2.9 CORRELATING GENE EXPRESSION AND ANXIETY-LIKE BEHAVIOR 
A Spearman correlation was used to compare BLA expression of the five genes of interest to 
anxiety-like behavior tested in the adult cohort (behavior separately reported [26]). Results were 
 17 
combined into anxiety-like Z-scores to reduce the complexity of the correlation analysis. The 
first step is to calculate the Z-score for each behavioral test measure (e.g., Z-EPM-
PercentCrossesOpenArms or Z-OF-PercentTimeCenter); this is performed by normalizing an 
individual mouse’s test measure to the mean and standard deviation of the comparison group. 
For all Z-scores, we used XX blank mice as the comparison group. The directionality of the Z-
score was adjusted such that increased values represented increased anxiety-like behavior (e.g., 
decreased time in the open arms of the elevated plus maze was considered increased anxiety-like 
behavior). We next calculated the Z-score for each mouse per behavioral test by averaging the 
two individual Z-measures for each test (e.g., averaging Z-EPM-TimeOpenArms and Z-EPM-
PercentCrossesOpenArms to get Z-EPM-Anxiety). Finally, the overall anxiety-like Z-score was 
calculated by averaging the Z-EPM-Anxiety and Z-OF-Anxiety scores. Correlations were 
performed between the Z-Anxiety measure for each mouse and expression of each gene (for the 
entire stressed cohort, as well as performed in groups based on main effects (XX vs. XY, ovaries 
vs. testes, and blank vs. testosterone treatment)) [16]. 
2.10 STATISTICAL ANALYSIS 
In adult mice, we used a three-way analysis of variance (ANOVA), (genetic sex x developmental 
gonadal sex x hormone treatment) to analyze the gene expression data from this cohort. In the 
developmental trajectory cohort, we used a two-way ANOVA, (genetic sex x developmental 
gonadal) to analyze dependent measures. We did not examine the main effects of hormone in the 
P16, P21 and P26 groups, as these mice did not receive hormone manipulations. However, in the 
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developmental cohort, we correlated testosterone levels with gene expression using Pearson 
correlation to determine whether endogenous testosterone levels affected gene expression. If the 
ANOVA was significant for any main effect or interaction, we performed planned comparisons 
using Tukey’s post hoc test. We did not correct for multiple testing in these studies, as we had a 
priori hypotheses for these genes to be altered based on our findings in the frontal cortex of FCG 
mice and in human postmortem brain tissue of patients with MDD [23, 24, 26].  Data are 
expressed as mean ± SEM, and significance was set at p < 0.05 [16]. 
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3.0  RESULTS 
3.1 EXPERIMENT 1: ADULTS (COHORT 1) 
The adult FCG mice in cohort 1 were gonadectomized and given testosterone or blank capsules 
at 15-weeks old. Mice were subjected to 8 weeks of UCMS to induce elevated anxiety-
/depressive-like behaviors. Importantly, adult mice treated with testosterone did not differ in 
testosterone levels and had significantly higher testosterone levels when compared to blank-
treated mice [16]. Compared to XX mice, XY mice had significantly lower Sst expression in the 
BLA (p < 0.04; Fig. 3A). There was no effect of genetic sex on expression of Gad67, Gad65, 
TrkB, or Bdnf in the BLA (p > 0.1 for all comparisons; Fig. 3B-E). There were no gonadal sex 
differences on expression of Sst, Gad67, Gad65, TrkB, or Bdnf in the BLA (p > 0.1 for all 
comparisons; Fig. 3A-E). We found a main activational effect of testosterone exposure on Sst, 
with testosterone increasing Sst expression (p < 0.04; Fig. 3A). There was also a main effect of 
circulating testosterone on BLA Bdnf expression (p < 0.03; Fig. 3E) with testosterone decreasing 
BLA Bdnf expression. There was no effect of testosterone on expression of Gad67, Gad65, or 
TrkB expression the BLA (p > 0.2 for all comparisons; Fig. 3B-D). In graphs representing results 
in this cohort, we show graphs summarized by main effects [XX (n = 61), XY (n = 51); F 
(n=56), M (n = 56); B (n = 55), T (n = 57)].  
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Figure 3: Main effects of sex-related factors on GABA- and Bdnf-related gene expression in the BLA 
of adult stressed mice.  
(A) XY mice had lower expression of Sst. Additionally, mice treated with testosterone had higher Sst expression. 
There was no genetic sex effect on expression of Gad67 (B), Gad65 (C), TrkB (D), or Bdnf (E). Gonadal sex did not 
influence expression of any gene (A–E). Testosterone significantly increased expression of Sst (A) and decreased 
expression of Bdnf (E), but did not affect expression of Gad67 (B), Gad65 (C), or TrkB (D). Numbers at the base of 
the bars indicate N. *p < 0.05; #, p < 0.1. T, testosterone, B, blank, F, gonadal female, M, gonadal male[16] 
. 
3.1.1 Correlation between gene expression and anxiety-like behavior 
Given the potential links between GABA- and BDNF-related gene expression and mood (see 
Literature Review), we next probed for potential correlations between anxiety-like behavior and 
BLA gene expression. We previously studied these same genes in the frontal cortex of FCG 
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mice, but the gene expression results did not match the behavioral results. In the BLA, we found 
that Sst expression was negatively correlated with anxiety-like behavior (p = 0.041; (i.e., higher 
Sst expression levels were correlated with decreased anxiety-like behavior). There was also a 
trend (p = 0.077) for a positive correlation between Bdnf expression and anxiety-like behavior 
(i.e., higher Bdnf expression levels were correlated with increased anxiety-like behavior). There 
were no other significant correlations between anxiety-like behavior and expression of the 
remaining genes (Gad67, Gad65, TrkB; p > 0.25 for all comparisons). Anxiety-like behaviors 
(Fig. 4E) are measured in z-scores and separated by main effects of genetic, gonadal, and 
circulating hormone treatment. XY mice had significantly higher anxiety-like behavior than XX 
mice. There was no significant difference between gonadal females and gonadal males. 
Testosterone treated-mice had significantly lower anxiety-like behavior than blank-treated mice. 
Sst expression (Fig. 4F) shows that XY mice have lower expression than XX mice and mice that 
received a testosterone capsule had significantly increased Sst expression compared to blank-
treated mice. 
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Figure 4: Behavioral assays after UCMS reveal an inverse relationship between anxiety-like behavior 
and expression of Sst in the BLA adult stressed mice.  
(A) Post-UCMS elevated plus maze (EPM) results for time and (B) Percent crosses into open arms. (C) Post-UCMS 
Open Filed (OF) results for time and (D) Percent distance in the center[26]. (E) Data from A-D were combined to 
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calculate anxiety-like behavior Z-scores (see Correlating gene expression and anxiety-like behavior above). Genetic 
males exhibited more anxiety-like behaviors than genetic female mice. Testosterone (T)-treated mice exhibited 
lower anxiety-like behaviors than blank (B)-treated mice. (F) Sst expression is lower in XY mice compared to XX 
mice, but testosterone-treated mice had increased Sst expression in the BLA compared to blank-treated mice. 
Numbers at the base of the bars in the graph on the right indicate N. Error bars indicate mean ± SEM. ***p < 0.001; 
**p < 0.01; *p < 0.05; #p < 0.1. F, gonadal female, M, gonadal male, B, blank, T, testosterone.  
3.2 EXPERIMENT 2: DEVELOPMENTAL COHORT (COHORT 2)  
Gonadally intact FCG mice (XXF, XXM, XYF, XYM) were sacrificed at three developmental 
time-points from late postnatal through early adolescence: P16 (pre-weaning), P21 (at time of 
weaning), and P26 (post-weaning). We then examined the effects genetic and gonadal sex (i.e., 
organizational effects of hormones) on expression of the same GABA- and BDNF-related genes 
in the BLA. 
3.2.1 P16 
We found an effect of genetic sex on expression of Sst (p < 0.01) and TrkB (p < 0.001) in the 
BLA, with XY mice having lower expression of both genes compared to XX mice (Fig. 5A, D). 
With respect to Sst, this is the same genetic sex effect we observed in the BLA of adult stressed 
mice. There was no effect of genetic sex on Gad67 (Fig. 5B), Gad65 (Fig. 5C), or Bdnf (Fig. 5E) 
expression in the BLA. Compared to gonadal females, there was a trend for gonadal males to 
have higher expression of Bdnf (p = 0.088; Fig. 5E).  There was no significant main effect of 
gonadal sex, however, on expression of Sst, Gad67, Gad65, or TrkB in the BLA (p > 0.3 for all 
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comparisons; Fig. 5A-D). There were no significant interactions between genetic and gonadal 
sex (p > 0.3 for all comparisons). In graphs representing results for P16, P21, and P26, we show 
graphs summarized by main effects.  
As expected, gonadal males had higher testosterone levels than gonadal females (M 0.233 
ng/mL ± 0.02; F 0.170 ng/mL ± 0.07; p < 0.01; Fig. 6A). Four subjects were eliminated due to 
testosterone levels outside of the expected normal circulating hormone levels and were excluded 
from gene expression analysis. Importantly, there were no significant differences in circulating 
testosterone between XX and XY mice (XX 0.211 ng/mL ± 0.02; XY 0.192 ng/mL ± 0.01; p > 
0.3) Further, testosterone levels at P16 did not differ between XXM and XYM mice (XXM 0.137 
ng/mL ± 0.01; XYM 0.139 ng/mL ± 0.011; p > 0.45; Fig. 6A), suggesting that the genetic sex 
difference does not affect testosterone levels in gonadal males.  
Additionally, circulating testosterone did not correlate with expression levels of any gene 
of interest (p > 0.5 for all correlation analyses). Together, this suggests that any difference in 
gene expression we might observe based on gonadal sex at P16 will be due to organizational 
effects of hormones rather than activational effects of testosterone.  
 25 
 
Figure 5: Main effects of GABA-related and BDNF-related gene expressin in the BLA of P16 Mice 
XY mice had lower expression of Sst (A) and TrkB (D) than XX mice; there was no effect of genetic sex on Gad67 
(B), Gad65 (C), or Bdnf expression (E). Gonadal males (M) had significantly higher expression of Gad65 (C) and 
Bdnf (E); there were no gonadal sex effects on Sst (A), Gad67 (B), and TrkB (D). Numbers at the base of the bars 
indicate N. **p < 0.01; *p < 0.05; #p < 0.1. F, gonadal female, M, gonadal male. 
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Figure 6: P16, P21, and P26 Testosterone Concentrations Compared Genetically and Gonadally 
Gonadal males had higher testosterone levels at P16 (A), P21 (B), and P26 (C). There was no effect of genetic sex 
on testosterone levels at any age (A, B, C). Numbers at the base of the bars in the graph on the right indicate N. ***p 
< 0.001; **p < 0.01.  F, gonadal female, M, gonadal male.  
3.2.2 P21 
We found an effect of genetic sex, with XY mice having lower expression of Gad67 (p = 0.01; 
Fig. 7B), and Gad65 (p < 0.015; Fig. 7C), in the BLA compared to XX mice. We also found a 
trend for an effect of genetic sex on Sst (p < 0.07; Fig. 7A) and TrkB (p < 0.08; Fig. 7D) where 
XX mice have higher levels compared to XY mice.  There was no effect of genetic sex 
on Bdnf expression in the BLA (Fig. 7E, p > 0.1). Compared to gonadal females, gonadal males 
showed no significant difference in expression of Sst, Gad67, Gad65, TrkB, or Bdnf (p > 0.3 for 
all comparisons; Fig. 7A-E).  
There was not a genetic sex effect on circulating testosterone (XX 0.156 ng/mL ± 0.01; 
XY 0.160 ng/mL ± 0.02; p > 0.3; Fig. 6B) but there was a main effect of gonadal sex (M 
0.130 ng/mL ± 0.01; F 0.185 ng/mL ± 0.02; p < 0.01; Fig. 6B). Importantly, testosterone levels at 
P21 did not differ between XXM and XYM mice (XXM 0.181 ng/mL ± 0.02; XYM 
 27 
0.19 ng/mL ± 0.03; p > 0.45), suggesting that genetic sex did not influence testosterone levels in 
gonadal males. Additionally, circulating testosterone did not correlate with expression levels of 
any gene of interest (p > 0.5 for all correlation analyses). Together, this suggests that any 
difference in gene expression we might observe based on gonadal sex in weanlings will be due to 
organizational effects of hormones rather than activational effects of testosterone [16]. 
 
 
Figure 7: Sex differences in GABA-related and BDNF-related gene expression in the BLA of P21 
mice 
XY mice had lower expression of Sst (A), Gad67 (B), and Gad65 (C), and TrkB (D) compared to XX mice; there 
was no effect genetic sex on Bdnf expression (E). There were no organizational effects of hormones on expression of 
any gene investigated (A–E). Numbers at the base of the bars indicate N. **p < 0.01; *p < 0.05; #p < 0.1. F, gonadal 
female, M, gonadal male.  
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3.2.3 P26 
There was no effect of genetic sex on expression of Sst, Gad67, TrkB or Bdnf (p > 0.05 for all 
comparisons; Fig. 8A, B, D, E). We did find, however, a trend for an effect of genetic sex on 
Gad65, with XY mice having higher expression than XX mice (p = 0.068; Fig. 8C). There was 
no effect of gonadal sex on expression of Sst, Gad67, Gad65, TrkB, or Bdnf in the BLA (p > 0.1; 
Fig. 8A-E). There were no significant interactions between genetic and gonadal sex (p > 0.2 for 
all comparisons). 
At P26, gonadal males had significantly higher testosterone levels than gonadal females 
(M 0.499 ng/mL ± 0.06; F 0.122 ng/mL ± 0.007; p < 10-8; Fig. 6C). Four subjects were 
eliminated using the Graphpad Grubb’s Outlier Test due to testosterone levels outside the 
expected normal circulating hormone levels and were excluded from gene expression analysis.  
There were no genetic sex effects on circulating testosterone (XX 0.321 ng/mL ± 0.04; XY 0.301 
ng/mL ± 0.06; p > 0.3). Additionally, there was no significant difference between XXM and 
XYM mice (XXM 0.513 ng/mL ± 0.06; XYM 0.485 ng/mL ± 0.11; p > 0.3), suggesting that the 
genetic sex difference does not affect testosterone levels in gonadal males. Additionally, 
circulating testosterone did not correlate with expression levels of any gene of interest (p > 0.2 
for all correlation analyses). 
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Figure 8: Sex differences in GABA-related and BDNF-related gene expression in the BLA of P26 
mice 
There was no effect of genetic sex on Sst (A), Gad67 (B), TrkB (D), or Bdnf expression (E). XY mice had a trend for 
higher expression of Gad65 expression (C) compared to XX mice. There were no organizational effects of hormone 
on expression of any gene investigated (A-E). Numbers at the base indicate N. #p < 0.1.  F, gonadal female, M, 
gonadal male.  
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3.3 SUMMARY OF EXPERIMENTAL FINDINGS 
Table 1: Summary of experimental results. 
 
This table displays a summary of the experimental results of this study. Additionally, the results from a non-stressed 
adult cohort studied by another lab member are included to more completely visualize the proposed development 
trajectory [16]. ***, p < 0.001; **, p < 0.01; *, p < 0.05; #, p < 0.1; F, gonadal female, M, gonadal male, T, 
testosterone, B, blank.  
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4.0  DISCUSSION 
We discovered several sex-related differences in the GABA and BDNF systems in the BLA 
(Table 1). To isolate the specific effects of genetic sex, development gonadal sex, and 
activational effects of adult hormones, we used the FCG mice. In cohort 1, we investigated 
GABA- and BDNF-related genes in gonadectomized adult mice exposed to unpredictable 
chronic mild stress.  In cohort 2, we studied GABA- and BDNF-related genes in a developmental 
cohort across three time-points pre- and peri-pubertally: P16, P21, and P26.    
In cohort 1 (Fig. 3), we found a main effect of genetic sex on Sst expression the BLA, 
with genetic females having higher expression of Sst than genetic males (XX > XY) and an 
opposing main effect of male-like testosterone levels, where testosterone-treated mice had higher 
Sst expression compared to blank-treated mice. Behavioral testing in these mice revealed that 
genetic sex significantly influenced behavior as well, with XY mice exhibiting higher anxiety-
like behavior than XX mice (Fig. 4E). Also, mice with male-like testosterone exposure had 
significantly lower anxiety-like behavior compared to blank-treated mice (previously reported in 
[26]).  Higher testosterone levels correlated with lower anxiety-like behavior in the mice.  In 
cohort 2, we studied three developmental time-points. In P16 mice (Fig. 5), genetic sex 
significantly influenced expression of Sst and TrkB (XX > XY) and gonadal sex influenced 
Gad65 and Bdnf expression (F < M). In P21 mice (Fig. 7), XY mice had significantly lower 
expression of Gad67 and Gad65, and a trend for Sst and TrkB compared to XX mice.  In P26 
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mice (Fig. 8), we found a trending main effect of genetic sex where genetic male mice had 
higher expression of Gad65 than genetic female mice. Gonadal sex did not influence any of the 
five genes investigated. At all three developmental time-points, gonadal males had higher T 
levels compared to gonadal females (Fig. 6). There were no genetic sex differences in T levels at 
the three developmental time-points. 
Our lab investigated GABA- and BDNF-related gene expression in the BLA of adult 
FCG mice under stressed conditions (cohort 1) to further investigate the relationship between 
gene expression and anxiety-like behavior. A previous study in our lab aimed to understand the 
same gene expression in the frontal cortex, and this is where we initially found the main effect of 
genetic sex on the expression of Sst where XX > XY [26]. However, we found that testosterone 
did not influence Sst expression in the frontal cortex despite testosterone strongly decreasing 
anxiety-like behavior. These results encouraged us to investigate gene expression in another 
brain region of the corticolimibic circuit, such as the BLA, in the same mice that could 
potentially correlate with these behavioral results. Our human postmortem work suggested that 
SST was reduced in the BLA of depressed women, but not depressed men. Thus, we turned our 
focus in mice on the BLA as the node in the corticolimbic network that might mediate sex 
differences in mood. The pattern of Sst expression that we found in the BLA of mice (lower Sst 
levels in XY mice, with testosterone increasing Sst expression) is consistent with the behavioral 
results. Lower Sst expression in XY mice is accompanied by higher anxiety-like behavior, while 
an increase in Sst expression with testosterone treatment is accompanied by a decrease in 
anxiety-like behavior. Our correlation analysis of these results revealed a significant negative 
correlation between Sst expression and anxiety-like behavior; moreover, higher Sst expression is 
correlated with lower anxiety-like behavior. Our Sst results suggest that male genetic sex and 
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male-like testosterone levels have opposing effects on BLA expression to modulate behavior. It 
seems that high circulating testosterone is compensating for the genetic vulnerability in XY 
mice. The compensation hypothesis suggests that gonadal hormones may act to abolish innate 
sex differences determined by genetic sex [44]. We believe testosterone acts to increase gene 
expression in the BLA to prevent the undesirable effects of lower expression in genetic males. 
Although XY mice may have a genetic deficit of Sst expression, testosterone serves to increase 
Sst expression and mask this underlying male vulnerability [16]. This pattern has been observed 
in other studies, which ultimately serves to decrease male-female differences. [44, 45]. For 
instance, mouse experiments reveal testosterone treatment increases male sex behavior, but 
having a Y chromosome decreases male sex behavior. It is thought that the genes on the X 
chromosome act to compensate for the unequal androgen experiences between males and 
females [45].  We previously found reduced SST expression in both the sgACC and DLPFC of 
both males and females with MDD, but reduced SST expression in the BLA was only found in 
females with MDD. The action of Sst that we revealed in cohort 1 may be in accordance with 
female vulnerability to MDD, as females do not typically have high levels of circulating 
testosterone [16].  
Our testosterone findings in cohort 1 that show decreased anxiety-like behavior and 
increased expression of GABA-related genes are consistent with findings in both humans and 
rodents. For example, androgen insensitive males show higher levels of mood disorders ([46-
50]). Low testosterone in human males is also associated with higher anxiety levels, but 
testosterone treatments reduce their anxiety [51, 52]. Rodent studies also report similar anti-
anxiety effects of testosterone. Rats with testicular feminization mutation (Tfm) of the androgen 
receptor, both spontaneous and induced, have elevated anxiety-like behaviors compared to 
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wildtype males and females. Our results for the effect of testosterone on GABA and BDNF-
related gene expression suggest the anti-anxiety effects of testosterone may be mediated by 
expression of these mood-related genes. Together, we hypothesize that men might be protected 
from anxiety and MDD via effects of testosterone on SST in the BLA.   
When comparing non-stressed to stressed cohorts, we discovered interesting patterns of 
gene expression that allow us to construct an interpretation of the GABA and BDNF systems 
under these conditions. For example, the opposing effects of male genetic sex and testosterone 
on Sst expression discussed earlier only emerged under stressed conditions (Fig. 3). Bdnf 
expression was also affected based on stress conditions where testosterone increased expression 
under non-stressed conditions, but testosterone decreased expression in mice under chronically 
stressed conditions. Additionally, some sex-related factors are masked by chronic stress. Both 
the effect of genetic sex on expression of TrkB and the organizational effect on Bdnf expression 
disappear under chronic stress conditions [16]. These results signify the complex relationship 
between GABA- and BDNF-related gene expression and stress conditions. 
Given the adult mice results, we asked whether there would be GABA- and BDNF-
related sex differences in the BLA during development. We chose time-points considered to be 
pre- and peripubertal: P16, P21, and P26. Studying gonadally-intact developing mice allowed us 
to understand the GABA- and BDNF-related gene expression that exists pre- and peripubertally.  
We believe that events like abuse and neglect during critical periods of development could lead 
to pathologies in gene expression that would make one more vulnerable to mood disorders upon 
stressful situations in adulthood.  
We found a main effect of genetic sex on expression of Sst and TrkB at P16. We also 
found a trend for a genetic sex effect of Sst and TrkB expression at P21. The main effect of 
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genetic sex in Sst and TrkB expression is present at P16, suggesting that this genetic sex 
difference originates at an earlier time point in the BLA (earlier than P16). The main effect of 
gonadal sex on circulating testosterone levels at P26 was more exaggerated than at P21, 
suggesting more pronounced gonadal hormone synthesis at this older age. It is interesting to note 
that even at these time-points before puberty, gonadal males still have higher testosterone levels 
than gonadal females. Our lab is conducting follow-up experiments to investigate gene 
expression of these same five genes in the BLA and circulating testosterone levels of P0 mice 
(the day of birth) to see if these sex effects are evident at birth.  
The P16, P21, and P26 time-points are all within the organizational window in which sex 
differences in hormone exposure cause permanent sex differences. These time-points also, 
overlap with the well-known developmental trajectory of mood. The genetic sex differences in 
gene expression were present at P16 through P21. By P26, however, these differences almost 
completely disappear, with the exception of Gad65 where there is a trending genetic sex 
difference (XX < XY). This pattern suggests a naturally differing developmental trajectory of the 
GABA system between XX and XY mice where the GABA system in the XY mice develops 
later than XX mice. We believe that disrupting this development could lead to adult 
psychopathology. 
The developmental cohort results are quite interesting when considered in the context of 
previous studies conducted in our lab. We previously studied a cohort of gonadectomized mice 
under non-stressed conditions [16]. Interestingly, TrkB expression was influenced by genetic sex 
(XX > XY) and Bdnf expression was influenced by both gonadal sex and hormone treatment (F 
< M; blank > testosterone) in the BLA of non-stressed mice (Table 1). Additionally, we found 
that the Sst expression observed at P16 and P21 is similar to the Sst expression in adulthood 
 36 
under chronic stress conditions (XX > XY). Sst, Gad67, and Gad65 expression of the non-
stressed cohort revealed no main effects, just like at P26. Interestingly, this main effect of genetic 
sex in Sst expression before puberty seems to disappear in adulthood, and only reemerges under 
stress conditions in adulthood. It appears that by P26, the gene expression in XY mice have 
caught up to XX mice. We predict that if we were to study a time-point between P26 and 
adulthood, we would find similar gene expression results to P26.  
The peak of the effect of genetic sex on GABA- and BDNF-related gene expression 
appears to be at P21. Four out of the five genes of interest are significantly affected (XX > XY). 
As a general pattern, Sst expression and TrkB expression seem to move together over the course 
of development. In adulthood, the genetic sex effect on TrkB persists in non-stressed adults and 
the effect of stress eliminates this difference. The opposite happens for Sst expression; the 
genetic sex effect reappears under stressed conditions. Perhaps these results suggest an inverse 
relationship between the GABA and BDNF systems in adulthood under different stress 
conditions. Gad65 and Bdnf expression also seem to move in concert with each other over the 
course of development. Gad65 expression is significantly different in either genetic or gonadal 
sex before and during puberty, but this difference disappears in adulthood under both non-
stressed and stressed conditions. While Bdnf is trending for an effect of gonadal sex at P16, 
expression is not significantly affected until adulthood. The effect of testosterone on Bdnf 
expression has opposite responses to stress conditions in adulthood: testosterone increases Bdnf 
in non-stressed mice, but decreases Bdnf expression in stressed mice. Our gene expression results 
highlight the intricate relationships between the GABA and BDNF systems over the course of 
development and under stress conditions.  
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There are a few limitations of our studies that I want to address. First, the FCG mice 
model is an artificial system that is not equivalent to male and female mice or humans. This 
model is necessary for our studies, however, to differentiate the sex-related factors that underlie 
the sex differences that are observed in wild-type mice and in humans. Testosterone levels also 
may vary by genetic sex during development. Although we did not test for testosterone levels at 
every point of development, we did not find a genetic sex difference in testosterone 
concentrations at P16, P21, or P26. Thus, our reported effects based on genetic sex are not 
confounded by potential differences in gonadal hormones. We used testosterone as our hormone 
treatment because it can be converted into estradiol in the brain. Thus, testosterone can act at 
both estrogen and androgen receptors. We will need to study receptor specificity in future 
studies, however, as our current study does not specify which receptors are in fact driving the 
effect of testosterone. We also did not compare our stressed and non-stressed cohorts at the same 
time. Using tissue homogenate of the BLA masks any cell-specific changes that may be 
occurring. We would have to change our methods moving forward, such as using laser 
microdissection of certain cell types, to identify cell-specific changes.  
In conclusion, I found differential expression of GABA- and BDNF-related genes in the 
BLA that illustrates a different developmental trajectory of these systems between the genetic 
sexes. Together, my results suggest that gene expression pre- and peripubertally that make up the 
developmental trajectory overlap well with the developmental trajectory of mood. My studies 
support the hypothesis that testosterone acts on SST in the BLA to affect mood. The genetic sex 
differences in the developmental trajectory of the GABA system and the influence of circulating 
testosterone uncovered in my studies could affect adult susceptibility to mood disorders.  
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APPENDIX 
THE EFFECT OF SEX-SPECIFIC FACTORS ON SEROTONIN- AND DOPAMINE-
RELATED GENE EXPRESSION IN THE BASOLATERAL AMYGDALA OF ADULT 
STRESSED MICE 
A.1 INTRODUCTION 
A.1.1 Serotonin in Major Depressive Disorder 
Serotonin (5-Hydroxytryptamine) is one of the monoamine neurotransmitters. Synthesis of 
serotonin depends on the level of the essential amino acid tryptophan and the activity of its rate 
limiting enzyme, tryptophan hydroxylase [53] (Figure 9).  
 
Figure 9: Serotonin synthesis pathway. 
 39 
Serotonin is created by converting tryptophan into 5-hydroxytryptophan via the rate limiting enzyme tryptophan 
hydroxylase. This intermediate is then converted into 5-hydroxytrypamine (serotonin) via the enzyme aromatic 
amino acid decarboxylase (AADC). 
 
Serotonin is largely found in the gastrointestinal tract and other tissues in the 
periphery[54]. Serotonin neurons in the brain are primarily located in the raphe nucleus and have 
widespread projections to have coordinated actions affecting mood, anxiety, and circadian 
rhythms [55, 56]. To measure serotonin metabolism from the central nervous system, a spinal tap 
is performed to measure 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin [57, 
58]. Only 1-2% of total serotonin concentration is found in the brain, yet serotonin has been 
found to have an active role in mood regulation, behavior, and psychopathology etiology and 
treatment [59].  
Evidence for serotonin involvement in major depressive disorder (MDD) includes 
decreased tryptophan, the amino acid from which serotonin is made [60, 61]. MDD also exhibits 
decreased serotonin metabolites, such as 5-Hydroxyindoleacetic acid (5-HIAA),  in the 
cerebrospinal fluid [58]. Altered markers of transmission in the frontal cortex and of midbrain 
factors involved in serotonin production suggests ineffective subcortical-cortical serotonergic 
transmission [62]. Extensive rodent studies have explored the link between the serotonin system 
and anxiety-/depressive-like behaviors [63, 64].  Other studies revealed sex differences in the 
serotonin system in both human and rodent systems [65, 66]. Interestingly, studies have shown 
that depressed women respond better to selective serotonin reuptake inhibitors (SSRIs) than men 
[67].  
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A.1.2 Dopamine in Major Depressive Disorder 
Dopamine is a catecholamine derived from the amino acid tyrosine, which is present at saturated 
concentrations in the body. The rate-limiting enzyme in this monoamine’s synthesis pathway is 
tyrosine hydroxylase (Figure 10). 
 
Figure 10: Dopamine synthesis pathway. 
Dopamine is created by first converting tyrosine into L-DOPA via the rate limiting enzyme tyrosine hydroxylase. L-
DOPA is then converted to Dopamine via the enzyme aromatic amino acid decarboxylase (AADC).  
 
There is strong evidence that dopamine is involved in the anticipation of reward and the 
motivation to gain rewards [68-72]. Dopamine is commonly known to be involved in modulating 
these emotional responses, but it also has had implications in the pathophysiology of depression 
as well as antidepressant medication mechanisms [73, 74]. In response to antidepressant 
treatment, dopaminergic neurotransmission is altered [75-78]. To measure dopamine metabolism 
from the central nervous system, a spinal tap is performed to measure homovanillic acid (HVA) 
[79]. 
It has been hypothesized that altered dopamine function underlies anhedonia and 
amotivational behaviors in depression [73, 80]. Evidence for dopamine involvement in MDD 
includes both postmortem and imaging studies suggesting changes in receptor levels, yet these 
results remain uncertain [81-83]. Optogenetic studies demonstrate a causal link between ventral 
tegmental area (VTA) dopaminergic neuron firing and anhedonia-like behavior in mice [84]. 
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Human imaging studies reveal dopamine-related sex differences in the frontal cortex of control 
subjects, where women have increased dopamine D2-like receptors compared to men [85]. There 
is conflicting evidence that indicates depressed patients have lower metabolites of dopamine in 
the cerebrospinal fluid, suggesting dopamine hypofunction [86].  However, subsequent rodent 
studies reveal sex differences in the dopamine system and report lower dopamine levels and 
higher turnover in the frontal cortex of female rats when compared to male rats (i.e., higher 
HVA/DA ratio in female rats) [35, 87]. 
A.1.3 Serotonin and Dopamine in the frontal cortex of FCG Mice 
Our lab previously studied expression of serotonin- and dopamine-related genes in the frontal 
cortex of FCG mice exposed to unpredictable chronic mild stress (UCMS). Results were 
previously reported in [35]. Overall, we found main effects of genetic sex, gonadal sex, and 
circulating testosterone on expression of genes coding for serotonin and dopamine receptors, 
components of both the cAMP/PKA and AKT signal transduction pathways, and other serotonin 
related genes in the frontal cortex of these mice. Specifically, genetic sex was the main factor 
influencing serotonin- and dopamine-related gene expression in the frontal cortex under chronic 
stress conditions [35]. These results were quite interesting to us and led us to formulate two 
alternative hypotheses when studying expression of these same pathways in the basolateral 
amygdala (BLA). We aimed to determine if effects of these sex-specific factors are 1) brain-wide 
in serotonin- and dopamine systems or if 2) the genetic sex differences observed in the previous 
study were specific to the frontal cortex. The frontal cortex and the BLA are both regions 
involved in the corticolimbic neural network of mood regulation [3], with the frontal cortex 
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providing top-down processing and the amygdala providing bottom-up processing [88]. Top-
down processing and bottom-up processing are two different responses to sensory stimuli in the 
environment. Top-down processing refers to the perception of information via cognition while 
bottom-up processing refers to the perception of information via the external stimulus itself [89]. 
There is a dynamic interplay between these two processes when one is tasked with processing 
sensory information. An emotionally salient stimulus that evokes a fear response, such as seeing 
a snake in the woods, is an example of bottom-up processing. Conversely, realizing that the 
“snake” in the woods was actually a stick is an example of top-down processing. Since our lab 
has studied gene expression in the frontal cortex extensively, we decided to study BLA, which is 
at the opposite end of this circuit, with the goal of understanding the relationship between these 
two regions. 
A.2 METHODS 
A.2.1 Mice 
This study utilized a unique strain of mice called the Four Core Genotypes (FCG) mice. In a 
wildtype mouse, genetic sex and gonadal sex are entirely linked due to the testes-determining 
gene, Sry, on the Y chromosome. This means that if a wildtype organism has a Y chromosome, 
they have Sry, and therefore, will develop gonadally male (both genetically and gonadally male). 
If a wildtype organism does not have a Y chromosome, they do not have Sry, and therefore, will 
develop gonadally female (both genetically and gonadally female). Using genetic engineering, 
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the Sry gene was removed from the Y chromosome and placed on an autosome instead, thereby 
decoupling genetic and gonadal sex.   
The FCG mice used in these studies (originating from Jackson Laboratories, Bar Harbor, 
ME, USA; B6.Cg- Tg(Sry)2Ei Srydl1Rlb/Arnoj) were generated by crossing a C57BL/6J female 
with an XY-Sry male. Y- indicates the absence of Sry on the Y chromosome, with Sry present 
instead as an autosomal transgene. Here, we use the male (M) and female (F) designation to 
indicate gonadal sex. This cross yielded four groups of mice: XXM (XXSry), XXF (XX), XYM 
(XY-Sry) and XYF (XY-). These four genotypes allow us to investigate the effects of genetic sex 
and developmental gonadal sex (i.e., organizational effects of hormones) independent of the 
other, as genetic sex and gonadal sex are inherited independently in this model. The addition of a 
testosterone or blank capsule (discussed below) after gonadectomy in adulthood also allows us to 
investigate the effects of circulating hormones (i.e., activational effects of testosterone). The 
mice were maintained under standard conditions (12-hour light and dark cycles; 22 ± 1°C, food 
and water ad libitum), in accordance with the University of Pittsburgh Institutional Animal Care 
and Use Committee [16]. We studied the GABA-related gene expression in this same cohort of 
mice previously (Cohort 1).  
A.2.2 Gonadectomies and testosterone treatment 
Adult FCG mice were bilaterally gonadectomized at 15 weeks under isoflurane anesthesia to 
remove the endogenous source of circulating gonadal hormone. Half of each genotype was 
implanted with a subcutaneous testosterone-filled capsule containing 5-mm crystalline 
testosterone (1.57-mm ID x 2.41-mm OD) or with a similarly sized blank capsule [16]. [XXF + 
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B (n=10), XXF + T (n = 16), XYF + B (n=12), XYF + T (n=12), XXM + B (n=15), XXM + T (n 
= 14), XYM + B (n=10), XYM + T (n = 12)]. It is important to note that the concentration the 
testosterone capsules were at or slightly above physiologically normal male levels. After 
allowing 4 weeks for mice to recover from surgery and for hormone levels to equilibrate, the 
mice were exposed to 8 weeks of unpredictable chronic mild stress (UCMS; see details below). 
After 7 weeks of UCMS exposure, mice were assessed for anxiety-like behaviors in the elevated 
plus maze and open field (Figure 11). Mice were exposed to UCMS during behavior testing, thus 
the mice were exposed to UCMS for a total of 8 weeks.  
 
Figure 11: Experimental design for adult stressed mice. 
Mice were gonadectomized (GDX) at ~15 weeks of age and implanted subcutaneously with either a testosterone 
(T)-filled or blank capsule. After GDX, mice in cohort 1 were exposed to 8 weeks of unpredictable chronic mild 
stress (UCMS) followed by behavioral testing and were then sacrificed. At the time of sacrifice, the brains were 
harvested for gene expression analyses and bloods were collected for hormone assay [16]. 
A.2.3 Unpredictable Chronic Mild Stress 
Group-housed adult mice (gonadal sex and hormone treatment matched) were exposed to a 
randomized schedule of environmental stressors 7 days a week for 8 weeks, gradually increasing 
in intensity, starting with 1–2 separate stressors a day and ending with 4–5 stressors a day 
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(separately and in tandem with one another) during the final week, as performed previously in 
our lab [16, 26]. Disturbances included light cycle disruption, tilted cage (45° tilt), social stress 
(rotate mice into previously occupied cages), reduced space (limiting mice to 1/3 of typical space 
in cage), aversive smell (20 min of exposure to bobcat or fox urine), no bedding or wet bedding 
overnight, mild restraint (50-mL conical tube with air hole for 15 min), and forced bath 
(approximately 2 cm of 21°C water for 15–45 min). We assessed body weight and fur weekly to 
track progression of the UCMS syndrome. Behavior testing occurred while mice were still being 
exposed to UCMS. We previously reported frontal cortex gene expression results from this 
cohort [26, 35]. 
A.2.4 Processing of brain tissue: BLA dissection and gene expression analyses 
Bilateral micropunches (1mm bore punch) of the BLA (between Bregma −0.94 and −1.82 mm; 
[31]) were obtained from approximately six 160-μm thick coronal tissue sections cut on a 
cryostat within the boundaries created by the internal and external capsule. All tools were treated 
with RNase Zap to prevent RNases contamination. Punches were stored in RNase free 1.5mL 
tubes at −80°C prior to RNA extraction [16]. 
A.2.5 RNA extraction and cDNA synthesis 
Total RNA was extracted from BLA tissue punches using RNeasy Plus Micro Kits (Qiagen; 
Valencia, CA, USA). RNA was reverse-transcribed into complementary DNA (cDNA) using 
QScript cDNA Supermix (olido(dT) and random primers (Quanta Biosciences, Gaithersburg, 
MD, USA)) [16].  
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A.2.6 Gene Selection in the BLA 
Similar to our frontal cortex study, we utilized the Allen Brain Atlas to determine which 
serotonin- and dopamine-related genes have high expression in the basolateral amygdala (BLA) 
expression of mice. These genes with high BLA expression were selected for quantitative 
polymerase chain reaction (qPCR) analysis. We examined 13 genes related to serotonin and 
dopamine in the BLA of FCG mice: Adcy2, Adcy5, Adrbk2, Akt3, App, Cacna1a, Cdk5, Comt, 
Gsk3a, Gsk3b, Mapk1, Ppp1r1b, and Syn2 (See Table 2). 
Table 2: Serotonin and Dopamine Gene Selection in the BLA of Adult Mice. 
 
We selected serotonin- and dopamine-related genes that had high expression in the BLA according to the Allen 
Brain atlas. We previously analyzed expression of some of these genes in the frontal cortex of FCG mice [35]. 
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A.2.7 Quantitative Polymerase Chain Reaction (qPCR) 
Small PCR products were amplified on a MJ Research (Waltham, MA, USA) DNA Engine 
Opticon System for qPCR using universal PCR conditions (65 to 59 °C touch-down and 40 
cycles (10 s at 95°C, 10s at 59°C, and 10s at 72°C)). cDNA was amplified in 20-μL reactions 
(0.1 × SYBR Green, 3 mM MgCl2, 200 nM dNTPs, 200 nM primers, 0.25 unit Platinum Taq 
DNA Polymerase (Invitrogen, Carlsbad, CA, USA)) [16]. 
Samples were run in triplicate, and results were calculated as the geometric mean of 
relative intensities compared to three internal controls (actin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), and cyclophilin). Actin, GAPDH, and cyclophilin are considered 
good housekeeping genes because sex-related factors do not influence their expression or 
abundance, thus we consider them to be internal controls. The results are expressed as arbitrary 
signal (2-dCT × 10,000). Grubbs’ outlier test determined statistical outliers in gene expression 
values. These outliers were excluded from qPCR analysis [16].  
A.2.8 Statistical analysis 
We used a three-way analysis of variance (ANOVA), (genetic sex x developmental gonadal sex 
x hormone treatment) to analyze gene expression data. This is the same approach we used for 
Cohort 1 in the GABA study (see Methods). If the ANOVA was significant for any main effect 
or interaction, we performed planned comparisons using the Least Significant Difference (LSD) 
post hoc test. We did not correct for multiple testing in these studies, as we had a priori 
hypotheses for these genes to be altered based on our findings in the frontal cortex of FCG mice 
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and in human postmortem brain tissue of patients with MDD[23, 24, 26].  Data are expressed as 
mean ± SEM, and significance was set at p < 0.05 [16]. 
A.3 RESULTS 
Compared to XX mice, XY mice had significantly lower expression of App in the BLA (p 
< 0.04; Figure 4A). There was no effect of genetic sex on expression of Adcy2, Adcy5, Adrbk2, 
Akt3, Cacna1a, Cdk5, Comt, Gsk3a, Gsk3b, Mapk1, Ppp1r1b, or Syn2, (p > 0.2 for all 
comparisons). We found a trend for gonadal males to have higher expression of Adrbk2 
compared to gonadal females (p < 0.09; Figure 12B). There was no effect of gonadal sex on 
expression of Adcy2, Adcy5, Akt3, App, Cacna1a, Cdk5, Comt, Gsk3a, Gsk3b, Mapk1, Ppp1r1b, 
or Syn2 (p > 0.1 for all comparisons). There was also a trend for testosterone increasing 
expression of both Comt (p < 0.1; Figure 12C) and Mapk1 (p < 0.1; Figure 4D) in the BLA. 
There was no effect of testosterone on expression of Adcy2, Adcy5, Adrbk2, Akt3, App, Cacna1a, 
Cdk5, Gsk3a, Gsk3b, Ppp1r1b, or Syn2 (p > 0.1 for all comparisons).  
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Figure 12: Main effects of sex-specific factors on the serotonin- and dopamine-related genes in the 
BLA of adult stressed mice. 
 (A) XY mice had lower expression of App than XX mice. There was no effect of genetic sex on Adrbk2 (B), Comt 
(C), or Mapk1 (D). (B) There was a trend for an effect of gonadal sex on Adrbk2 expression. Gonadal sex did not 
influence expression of App (A), Comt (C), or Mapk1 (D). There was a trend for an effect of testosterone exposure 
on expression of Comt (C) and Mapk1 (D), but no effect of testosterone on expression of App (A) or Adrbk2 (B). 
Numbers at the base of the bars indicate N. *p < 0.05; #, p < 0.1. T, testosterone, B, blank, F, gonadal female, M, 
gonadal male. 
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We also found some interesting interactions between the main effects on expression of 
the serotonin- and dopamine-related genes in the BLA. There was a trend for an interaction 
between genetic sex and testosterone on Adcy2 expression (p = 0.053; Figure 13A); post hoc 
analysis revealed a trend for a difference between genetic females with and without testosterone 
treatment (XX+B vs. XX+T; p = 0.053) and a significant difference between genetic males 
treated with testosterone and genetic females treated with testosterone (XX+T vs. XY+T; p = 
0.041). There was a significant interaction of gonadal sex and testosterone on App expression (p 
= 0.031; Figure 13B); post hoc analysis revealed a difference between gonadal females with and 
without testosterone treatment (F+B vs. F+T; p = 0.012) and a difference between gonadal males 
treated with testosterone and gonadal females treated with testosterone (F+T vs. M+T).  There 
was a trend for an interaction between genetic sex and testosterone on Gsk3a expression 
(p=0.053 Figure 13C); post hoc analysis revealed a difference between genetic females treated 
with testosterone and genetic males treated with testosterone (XX+T vs. XY+T; p = 0.038), as 
well as a difference between genetic males with and without testosterone treatment (XY+B vs. 
XY+T; p = 0.052). Finally, there was a significant interaction between gonadal sex and hormone 
on Gsk3a expression (p=0.019; Figure 13D); post hoc analysis revealed a difference between 
blank-treated gonadal females and blank-treated gonadal males (F+B vs. M+B; p = 0.047) as 
well as a difference between gonadal males with and without testosterone treatment (M+B vs. 
M+T; p = 0.033). 
 
 51 
 
Figure 13: Interactions of sex-specific factors on serotonin- and dopamine-related gene expression in 
the BLA of adult stressed mice.  
 (A) There was a trend for testosterone to increase Adcy2 expression in XX mice, but no effect of testosterone in XY 
mice (B) Testosterone increases App expression in gonadal females but not gonadal males. (C) There was a trend for 
testosterone to decrease Gsk3a expression in XY mice, but no effect of testosterone in XX mice. (D) Testosterone 
treatment decreases Gsk3a expression in gonadal males, but not gonadal females. Numbers at the base of the bars 
indicate N. *p < 0.05; #, p < 0.1. T, testosterone, B, blank, F, gonadal female, M, gonadal male. 
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A.4 DISCUSSION 
We investigated the effects of genetic sex, developmental gonadal sex, and circulating 
testosterone on expression of several serotonin- and dopamine-related genes in the BLA of 
chronically stressed mice. We aimed to determine if sex-specific factors influenced serotonin- 
and dopamine-related gene expression in a brain-wide or region-specific fashion. We found a 
main effect of genetic sex on App expression in the BLA (Fig. 12A) with genetic females having 
higher expression than genetic males (XX > XY). We also found a trend for a main effect of 
gonadal sex on Adrbk2 expression in the BLA (Fig. 12B) with gonadal males trending for higher 
expression than gonadal females. Testosterone was found to have a trend for increasing the 
expression of Comt and Mapk1 in the BLA (Fig. 12C-D).  
Depending on the gene, my results support both hypotheses. For instance, the effect of 
genetic sex on App expression in the BLA is consistent with the results from our frontal cortex 
study in [35]. Specifically, in both the frontal cortex and BLA, XY mice have lower expression 
of App than XX mice. Thus, my results for App expression in the BLA support the brain-wide 
hypothesis. However, my results for other genes support the region-specific hypothesis. In the 
frontal cortex, there was an effect of circulating testosterone (T > B) and a trend for an effect of 
genetic sex (XX > XY) on Adcy2 expression [35]. In the BLA, however, there were no main 
effects in Adcy2 expression. Similarly, in the frontal cortex, there was a main effect of gonadal 
sex (F > M), a main effect of circulating testosterone (B > T), and a trend for an effect of genetic 
sex (XX > XY) on Akt3 expression [35]. There were no significant main effects found for Akt3 
expression in the BLA, thus supporting the region-specific hypothesis. My results further 
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illustrate the complexity of effects that sex-related factors have on expression of genes related to 
mood. 
We also found several interesting two-way interactions between genetic sex and hormone 
as well as gonadal sex and hormone. There was a trend for an interaction between genetic sex 
and testosterone on Adcy2 expression (p = 0.053; Fig. 13A). For instance, post hoc analysis 
revealed that testosterone treatment increased Adcy2 expression only in XX mice. This is 
interesting to consider, as the same hormone exposure is having different effects depending on 
genetic sex. There was a significant interaction of gonadal sex and testosterone on App 
expression (p = 0.031; Fig. 13B). Post hoc analysis revealed that testosterone increases App 
expression in only gonadal females. Thus, the same hormone exposure is producing different 
effects depending on gonadal sex. There was a significant interaction between gonadal sex and 
hormone on Gsk3a expression (p=0.019; Fig. 13D).  Post hoc analysis revealed that testosterone 
decreases Gsk3a expression in gonadal males only. There was also a trend for an interaction 
between genetic sex and testosterone on Gsk3a expression (p=0.053; Fig. 13C). Post hoc 
analysis revealed that testosterone decreases expression in XY mice only. These interactions are 
critical to understand, especially when considering future advancement in depression treatments. 
My studies demonstrate an important influence of genetic sex, developmental gonadal hormone, 
and adult circulating hormone on serotonin-, and dopamine-related gene expression in the BLA. 
Further, my results point out that the serotonin and dopamine systems in the BLA are not as 
affected by sex-specific factors as they are in the frontal cortex [35].  
Interestingly, depressed women tend to respond better to SSRI treatment than depressed 
men[67]. Thus, it is tempting to speculate that the serotonin system is more dysregulated in 
women with depression compared to men. Due to inherent differences (genetic sex, gonadal sex, 
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circulating hormones), men and women might have different underlying biological mechanisms 
of MDD. We found that testosterone affects serotonin and dopamine genes differently based on 
genetic or gonadal sex. Since men have higher testosterone concentrations than women, 
testosterone may protect against serotonin and dopamine deficits in men. The interactions 
uncovered in my study, therefore, emphasize the potential difference in responses to drug 
treatments between the sexes, which provides further evidence for the need for sex-specific 
treatment for depression. Considering the evidence above, it is possible that the differential 
response to SSRI treatment between men and women is due to differential interactions of sex-
specific factors. Treatment developers should take the interactions of these influences into 
consideration to ensure the effects novel drugs are consistent across all sex-specific factors.  
There are a few limitations of this study that I want to address. First, the FCG mice model 
is an artificial system that is not equivalent to male and female mice or humans. This model is 
necessary for our studies, however, to differentiate the sex-related factors that underlie the sex 
differences that are observed in wild-type mice and in humans. We did not correlate BLA 
serotonin- and dopamine-related gene expression with the behavioral results from this cohort. 
Perhaps this data can give us a deeper understanding of the effects of stress exposure on the 
serotonin and dopamine systems in the BLA. Since we found interesting results involving a 
possible protective effect of testosterone in males, we could study a cohort of blank-treated and 
testosterone-treated male and female mice with UCMS. We predict that the females treated with 
testosterone would be protected from serotonin deficits.  We also only studied BLA expression 
of serotonin- and dopamine-related genes in a stressed cohort of mice. In future studies, we will 
look at the serotonin- and dopamine-related genes in a non-stressed cohort of adult mice to add a 
control experiment. We may study serotonin- and dopamine-related gene expression in other 
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brain regions such as the hippocampus, dorsal striatum, and ventral striatum to gather further 
evidence for the two alternative hypotheses.  It is possible that one brain region may drive 
another brain region to have a certain level of activity; however, it is impossible to determine this 
from the studies conducted so far. To determine if the frontal cortex drives the amygdala, for 
instance, a follow-up study can be conducted that chronically inhibits neurons in the frontal 
cortex to see the effect on the BLA neuronal activity.  
To conclude, my study reveals the complex effects that sex-related factors have on 
expression of mood-related genes across brain regions. My results support both the brain-wide 
and region-specific hypotheses, depending on the gene of interest. Differential interactions of 
testosterone with both genetic and gonadal sex highlight the importance of considering inherent, 
physiological differences between men and women when developing treatments for depression 
to ensure therapeutic effects and proper treatment of underlying psychopathology.  
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